The previous year which witnessed rapidly growing virus's sudden contagion proved to be a "cash cow" for numerous biotech companies, which scrambled to accumulate enough money and staffers to initiate new research and design products to respond to the first documented flu pandemic in 40 years.

The H1N1 virus contributed in generating millions of dollars in revenue for the biotech firms as it assisted to lift some stock prices to new high levels, with some touching as much as 700 percent over the course of last year.

Frank Malinoski, a former MedImmune executive quoted, "The companies in the area now are either concentrating on how they can be part of the seasonal flu market or how they can prepare for the next pandemic."

The companies are currently revealed to evaluate their performance and lessons learned in 2009 to push for improving flu vaccine technology in time for the next outbreak.

Last year, the government extended $389 million for FluMist, the first vaccine to land in the hospitals.

The money generated assisted to convert a potential 5 percent slip in AstraZeneca's U. S. revenue into a 4 percent bump in the fourth quarter.